Iressa Survival Data Adequately Disseminated To Physicians/Patients, Cmte. Says
This article was originally published in The Pink Sheet Daily
Executive Summary
AstraZeneca communication to physicians/patients on Iressa survival data has been adequate, FDA Oncologic Drugs Advisory Committee says. FDA asks committee to discuss possibility of recommending Genentech/OSI Pharma’s Tarceva as alternative to Iressa in labeling, but committee resists.